| Literature DB >> 34791535 |
Hiroshi Yoshida1, Yuka Asami2,3, Mayumi Kobayashi-Kato4, Yasuhito Tanase4, Masaya Uno4, Mitsuya Ishikawa4, Kouya Shiraishi2, Tomoyasu Kato4.
Abstract
This study aimed to clarify the genetic features of endometrioid-type endometrial cancer arising in adenomyosis (EC-AIA) using targeted sequencing and immunohistochemistry (IHC) for both carcinoma and adjacent adenomyosis tissues. We identified three endometrioid-type EC-AIAs in 689 patients with endometrial cancer; two exhibited grade 3 endometrioid carcinoma. IHC revealed retained expression of PMS2, MSH6, ARID1A, and PAX2. Two of them showed diffuse strong p53 expression only in the carcinoma. PTEN expression was lost in carcinoma of only one of these cases. Carcinoma had many gene mutations than adjacent adenomyosis in all cases. KRAS and TP53 mutations were found in two of them. The other patient had mutations in KRAS, PIK3CA, and PPP2R1A. They were classified as two "p53-mutated" and one "non-specific molecular profile." These molecular alterations in endometrioid-type EC-AIA imply similar carcinogenesis to a subset of endometrial endometrioid carcinoma and might be used as targets of liquid biopsy after further validation.Entities:
Keywords: Adenomyosis; Endometrioid adenocarcinoma; Gene mutations; Immunohistochemistry; Molecular subtype
Mesh：
Substances：
Year: 2021 PMID： 34791535 DOI： 10.1007/s00428-021-03234-y
Source DB: PubMed Journal: Virchows Arch ISSN： 0945-6317 Impact factor: 4.064